Takeda’s investigational PPI TAK-390MR demonstrated higher healing rates comp…
Combined results from two Phase 3 studies presented at the American College of Gastroenterology Annual Scientific Meeting in Orlando, Fla., demonstrated that TAK-390MR resulted in higher healing rates than lansoprazole among patients with more severe grades of erosive esophagitis. TAK-390MR combines dexlansoprazole with a Dual Delayed Release formulation, designed to provide two separate releases of drug for extended duration of acid suppression.
More: continued here